New possibilities of drug therapy for obesity

• Andrey F. Verbovoy
• Yuliya A. Dolgikh

AbstractObesity is one of the most common non-communicable diseases. This pathology is a risk factor for the development of diabetes mellitus, as well as cardiovascular diseases: arterial hypertension, coronary heart disease, chronic heart failure. Most often, orlistat is used to treat obesity, which is represented in the pharmaceutical market by various generic drugs. One of such drugs is Orlistat 120 mg. The article presents the data of the All-Russian Observational Non-Interventional Program for Evaluation of the Efficacy and Safety Profile of the Orlistat 120 mg for weight loss in obese patients in clinical practice. The results of the study showed a significant reduction in all patients not only anthropometric parameters, but also systolic and diastolic blood pressure, as well as heart rate. In the analysis of adverse events, 18 (1.6%) of non-serious undesirable drug reactions were revealed in the course of the study. The revealed phenomena arose from the gastrointestinal tract and were caused by the pharmacological action of the drug, which prevents the absorption of fats coming from food. The frequency of undesirable drug reactions arising from the intake of Orlistat 120 mg is lower than when using other drugs containing orlistat. Thus, a significant positive effect of Listat's preparation on all, without exception, the parameters studied during the study, which are criteria for the effectiveness and safety of the therapy, was shown.

Keywords:obesity, treatment, orlistat

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)